Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 202

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers

Open access
Drilon, Alexander, Somwar, Romel, Mangatt, Biju P., Edgren, Henrik, Desmeules, Patrice, Ruusulehto, Anja, Smith, Roger S., Delasos, Lukas, Vojnic, Morana, Plodkowski, Andrew J., Sabari, Joshua, Ng, Kenneth, Montecalvo, Joseph, Chang, Jason, Tai, Huichun, Lockwood, William W., Martinez, Victor, Riely, Gregory J., Rudin, Charles M., Kris, Mark G., Arcila, Maria E., Matheny, Christopher, Benayed, Ryma, Rekhtman, Natasha, Ladanyi, Marc, Ganji, Gopinath·2018·Cancer Discovery

Abstract

NRG1 rearrangements are oncogenic drivers that are enriched in invasive mucinous adenocarcinomas (IMA) of the lung. The oncoprotein binds ERBB3–ERBB2 heterodimers and activates downstream signaling, supporting a therapeutic paradigm of ERBB3/ERBB2 inhibition. As proof of concept, a durable response was achieved with anti-ERBB3 mAb therapy (GSK2849330) in an exceptional responder with an NRG1-rearranged IMA on a phase I trial (NCT01966445). In contrast, response was not achieved with anti-ERBB2 therapy (afatinib) in four patients with NRG1-rearranged IMA (including the index patient post-GSK2849330). Although in vitro data supported the use of either ERBB3 or ERBB2 inhibition, these clinical results were consistent with more profound antitumor activity and downstream signaling inhibition with anti-ERBB3 versus anti-ERBB2 therapy in an NRG1-rearranged patient-derived xenograft model. Analysis of 8,984 and 17,485 tumors in The Cancer Genome Atlas and MSK-IMPACT datasets, respectively, identified NRG1 rearrangements with novel fusion partners in multiple histologies, including breast, head and neck, renal, lung, ovarian, pancreatic, prostate, and uterine cancers. Significance: This series highlights the utility of ERBB3 inhibition as a novel treatment paradigm for NRG1-rearranged cancers. In addition, it provides preliminary evidence that ERBB3 inhibition may be more optimal than ERBB2 inhibition. The identification of NRG1 rearrangements across various solid tumors supports a basket trial approach to drug development. Cancer Discov; 8(6); 686–95. ©2018 AACR. See related commentary by Wilson and Politi, p. 676. This article is highlighted in the In This Issue feature, p. 663

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-17-1004

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 202

Metadata

Authors
Drilon, A., Somwar, R., Mangatt, B. P., Edgren, H., Desmeules, P., Ruusulehto, A., Smith, R. S., Delasos, L., Vojnic, M., Plodkowski, A. J., Sabari, J., Ng, K., Montecalvo, J., Chang, J., Tai, H., Lockwood, W. W., Martinez, V., Riely, G. J., Rudin, C. M., Kris, M. G., Arcila, M. E., Matheny, C., Benayed, R., Rekhtman, N., Ladanyi, M., & Ganji, G.
Venue
Cancer Discovery
Published
2018-05-31
Volume
8
Issue
6
Pages
686-695
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2794723335
Cited by
202
References
2
FWCI
8.09
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-1004
The paper
Drilon, A., Somwar, R., Mangatt, B. P., Edgren, H., Desmeules, P., Ruusulehto, A., Smith, R. S., Delasos, L., Vojnic, M., Plodkowski, A. J., Sabari, J., Ng, K., Montecalvo, J., Chang, J., Tai, H., Lockwood, W. W., Martinez, V., Riely, G. J., Rudin, C. M., . . . Ganji, G. (2018). Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-1004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.